Effectiveness and Safety of Clofarabine Monotherapy or Combination Treatment in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia: A Pragmatic, Non-interventional Study in Korea
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Effectiveness and safety of clofarabine (one of the treatment mainstays in pediatric patients with relapsed/refractory acute lymphoblastic leukemia [ALL]) was assessed in Korean pediatric patients with ALL to facilitate conditional coverage with evidence development. Materials and Methods In this multicenter, prospective, observational study, patients receiving clofarabine as mono/combination therapy were followed up every 4-6 weeks for 6 months or until hematopoietic stem cell transplantation (HSCT). Response rates, survival outcomes, and adverse events were assessed. Results Sixty patients (2-26 years old; 65% B-cell ALL, received prior ≥ 2 regimen, 68.3% refractory to previous regimen) were enrolled and treated with at least one dose of clofarabine; of whom 26 (43.3%) completed 6 months of follow-up after the last dose of clofarabine. Fifty-eight patients (96.7%) received clofarabine combination therapy. Overall remission rate (complete remission [CR] or CR without platelet recovery [CRp]) was 45.0% (27/60; 95% confidence interval [CI], 32.4 to 57.6) and the overall response rate (CR, CRp, or partial remission [PR]) was 46.7% (28/60; 95% CI, 34.0 to 59.3), with 11 (18.3%), 16 (26.7%), and one (1.7%) patients achieving CR, CRp, and PR, respectively. The median time to remission was 5.1 weeks (95% CI, 4.7 to 6.1). Median duration of remission was 16.6 weeks (range, 2.0 to 167.6 weeks). Sixteen patients (26.7%) proceeded to HSCT. There were 24 deaths; 14 due to treatment-emergent adverse events. Conclusion Remission with clofarabine was observed in approximately half of the study patients who had overall expected safety profile; however, there was no favorable long-term survival outcome in this study.
Abstract
Purpose Effectiveness and safety of clofarabine (one of the treatment mainstays in pediatric patients with relapsed/refractory acute lymphoblastic leukemia [ALL]) was assessed in Korean pediatric patients with ALL to facilitate conditional coverage with evidence development. Materials and Methods In this multicenter, prospective, observational study, patients receiving clofarabine as mono/combination therapy were followed up every 4-6 weeks for 6 months or until hematopoietic stem cell transplantation (HSCT). Response rates, survival outcomes, and adverse events were assessed. Results Sixty patients (2-26 years old; 65% B-cell ALL, received prior ≥ 2 regimen, 68.3% refractory to previous regimen) were enrolled and treated with at least one dose of clofarabine; of whom 26 (43.3%) completed 6 months of follow-up after the last dose of clofarabine. Fifty-eight patients (96.7%) received clofarabine combination therapy. Overall remission rate (complete remission [CR] or CR without platelet recovery [CRp]) was 45.0% (27/60; 95% confidence interval [CI], 32.4 to 57.6) and the overall response rate (CR, CRp, or partial remission [PR]) was 46.7% (28/60; 95% CI, 34.0 to 59.3), with 11 (18.3%), 16 (26.7%), and one (1.7%) patients achieving CR, CRp, and PR, respectively. The median time to remission was 5.1 weeks (95% CI, 4.7 to 6.1). Median duration of remission was 16.6 weeks (range, 2.0 to 167.6 weeks). Sixteen patients (26.7%) proceeded to HSCT. There were 24 deaths; 14 due to treatment-emergent adverse events. Conclusion Remission with clofarabine was observed in approximately half of the study patients who had overall expected safety profile; however, there was no favorable long-term survival outcome in this study.
참고문헌 (34)
- Kato M, "Treatment and biology of pediatric acute lymphoblastic leukemia", Pediatr Int, 60, pp.4~12 (2018)
- Boer JM, "BCR-ABL1-like acute lymphoblastic leukaemia : from bench to bedside", Eur J Cancer, 82, pp.203~218 (2017)
- "F1000Res", 2016, 2635~
- 박현진, "Incidence and Survival of Childhood Cancer in Korea", Cancer Research and Treatment, 48(3), pp.869~882 (2016), 대한암학회
- 김혜리, "소아 급성백혈병 치료의 최신지견", 대한의사협회지, 59(9), pp.690~697 (2016), 대한의사협회[DOI]
- Pui CH, "Recent research advances in childhood acute lymphoblastic leukemia", J Formos Med Assoc, 109, pp.777~787 (2010)
- 주희영, "Advancements in the treatment of pediatric acute leukemia and brain tumor - continuous efforts for 100% cure", Clinical and Experimental Pediatrics, 57(10), pp.434~439 (2014), 대한소아청소년과학회
- Ceppi F, "Improvement of the outcome of relapsed or refractory acute lymphoblastic leukemia in children using a risk-based treatment strategy", PLoS One, 11, pp.e0160310~ (2016)
- Fuster JL, "Current approach to relapsed acute lymphoblastic leukemia in children", World J Hematol, 3, pp.49~70 (2014)
- Duval M, "Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure", J Clin Oncol, 28, pp.3730~3738 (2010)
- Inagaki J, "Hematopoietic stem cell transplantation following unsuccessful salvage treatment for relapsed acute lymphoblastic leukemia in children", Pediatr Blood Cancer, 62, pp.674~679 (2015)
- Jeha S, "Clofarabine for the treatment of acute lymphoblastic leukemia", Expert Rev Anticancer Ther, 7, pp.113~118 (2007)
- Raetz EA, "Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?", Hematology Am Soc Hematol Educ Program, 2012, pp.129~136 (2012)
- Pession A, "Use of clofarabine for acute childhood leukemia", Biologics, 4, pp.111~118 (2010)
- 유건희, "재발성", 불응성 소아 급성림프모구백혈병 환자의 치료 경향 및 성적에 대한 다기관 후향적 관찰 연구, 2017, pp.24(2), 101~106[DOI]
- Yoo SL, "Improving patient access to new drugs in South Korea : evaluation of the national drug formulary system", Int J Environ Res Public Health, 16, pp.e288~ (2019)
- Bennett JM, "Proposals for the classification of the acute leukaemias. French-American-British (FAB) Co-operative Group", Br J Haematol, 33, pp.451~458 (1976)
- Jeha S, "Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia", J Clin Oncol, 24, pp.1917~1923 (2006)
- Hijiya N, "Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia", Blood, 118, pp.6043~6049 (2011)
- Locatelli F, "Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory", multiple relapsed acute lymphoblastic leukaemia, 2009, pp.147, 371~378
- Nguyen K, "Factors influencing survival after relapse from acute lymphoblastic leukemia : a Children’s Oncology Group study", Leukemia, 22, pp.2142~2150 (2008)
- Bonate PL, "Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer", Cancer Chemother Pharmacol, 67, pp.875~890 (2011)
- Barreto JN, "Antineoplastic agents and the associated myelosuppressive effects : a review", J Pharm Pract, 27, pp.440~446 (2014)
- Nordvig J, "Febrile neutropenia and long-term risk of infection among patients treated with chemotherapy for malignant diseases", Open Forum Infect Dis, 5, pp.ofy255~ (2018)
- "Highlights of prescribing information: Clolar (clofarabine)" (2015)[URL]
- von Stackelberg A, "Phase I", phase II study of blinatumomab in pediatric patients with relapsed, J Clin Oncol, pp.2016, 34[DOI]
- Jabbour E, "Outcome of patients with relapsed", refractory acute lymphoblastic leukemia after blinatumomab failure : no change in the level of CD19 expression, 2018, pp.93, 371~374
- Hucks G, "The journey to CAR T cell therapy : the pediatric and young adult experience with relapsed or refractory B-ALL", Blood Cancer J, 9, pp.10~ (2019)
- Maude SL, "Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia", N Engl J Med, 378, pp.439~448 (2018)
- Kenderian SS, "Chimeric antigen receptor T cells and hematopoietic cell transplantation : how not to put the CART before the horse", Biol Blood Marrow Transplant, 23, pp.235~246 (2017)
- Forsberg MH, "The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL", Ther Clin Risk Manag, 14, pp.1573~1584 (2018)
- Shah NN, "Mechanisms of resistance to CAR T cell therapy", Nat Rev Clin Oncol, 16, pp.372~385 (2019)
- Campana D, "Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia", Blood, 129, pp.1913~1918 (2017)
- Lovisa F, "Pre-and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia", Br J Haematol, 180, pp.680~693 (2018)